Clinical Response to Treatment with HeberFERON® in Patients with Basal Cell Carcinoma

Abstract

Introduction: Basal cell carcinoma is the most common cutaneous malignant tumor and has become an increasingly relevant public health problem worldwide. The existence of alternative treatments such as HeberFERON^® offers the advantage of minimizing or avoiding the negative consequences of surgery for patients with these tumors.

Objective: To determine the clinical tumor response in patients with basal cell carcinoma treated with HeberFERON^®.

Methods: A descriptive, longitudinal, prospective study was conducted. The population consisted of 111 patients with basal cell carcinoma treated at the Dermatology Service of Villa Clara province, who were treated with HeberFERON^® in the period from January 2018 to December 2019.

Results: The most frequently treated tumors were primary, located in the nose and cheek, ulcerative and nodular clinical subtype, nodular histological subtype, and size between one and two centimeters. Complete clinical response was achieved in 51.35% and partial response in 47.75% of cases. Only in one of them the disease remained stable (0.90%). There was no progressive disease in any patient. Mutilations were avoided.

Conclusions: A complete or partial clinical response was obtained in all treated patients and the relationship between clinical response and tumor size was observed.